Ads
related to: cardiovascular consultants
Search results
Are keto-like low-carb and high-fat diets harmful to your heart health
Investing.com· 5 days agoApolipoprotein B is a blood test to gauge the risk of heart disease.
World No Tobacco Day: Know how tobacco can harm your body
Investing.com· 11 hours agoNew Delhi, May 31 (IANS) Tobacco consumption devastates the human body in myriad ways. It affects...
The heart health risks for midlife women – and how to beat them
Daily Telegraph· 1 day agoAsked to picture a heart attack victim, most people would imagine a middle-aged, overweight man...
The seven signs of an unhealthy gut – and how to fix it
The Telegraph via Yahoo News· 3 days agoWe’ve long been told that “you are what you eat”, but only in recent years has research revealed...
Psoriasis Tied to Increased Risk for MACE Despite Statin Use
Medscape· 1 day agoOver a period of 5 years, the likelihood of major adverse cardiovascular events (MACE) in patients...
ACROSS OUR COMMUNITIES
Salem News· 12 hours agoPERI #59 will meet at 1 p.m. Monday, June 10, at First Christian Church, 225 E. Chestnut St., Lisbon. The speaker will be from Medicare Patrol on Medicare Fraud. Indigo Family Theater will present ...
Is Steak a Health Food Now?
GQ via Yahoo News· 2 days ago“Red meat is a whole food,” says Samantha Cassetty, a registered dietitian and nutrition consultant for the chain. “And what we want people to do is to...
Former senior NHS surgeon charged with sexually assaulting hospital staff
Daily Telegraph· 3 days agoA former senior NHS heart surgeon has been charged with sexually assaulting six members of staff at...
Metformin Initiation Cuts Gout Risk in Prediabetes
Medscape· 1 day agoMetformin use not only prevented the progression to diabetes but also lowered the risk for gout in individuals with prediabetes.
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KTLA-TV Los Angeles· 6 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...